Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases

Archivum Immunologiae et Therapiae Experimentalis

Volumn 52, Issue 2, 2004, Pages 69-82

  Cetkovic Cvrlje, Marina ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

Allergy; Allogeneic transplantation; JAK3 inhibitors; Janus kinase 3 (JAK3); Type 1 diabetes

Indexed keywords

4 (3 BROMO 4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3,5 DIBROMO 4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; CT 2576; CT 5589; CYTOVARICIN; CYTOVARICIN B; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LEFLUNOMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PNU 156804; QUINAZOLINE DERIVATIVE; STAT PROTEIN; TYRPHOSTIN; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; STREPTOZOCIN DIABETES; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; ENZYME INHIBITORS; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION; JANUS KINASE 3; LEUKEMIA; MICE; PROTEIN-TYROSINE KINASES; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 2542430084     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Aizawa S., Kamisaku H. and Sado T. (1995): An MHC-compatible allogeneic bone marrow donor with a distinct role of T-cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease. Bone Marrow Transplant., 16, 603-609.
2. Apperly J. F., Jones L., Hale G., Waldmann H., Hows J., Rombos Y., Tsatalas C., Marcus R. E., Goolden A. W., Gordon-Smith E. C., Catovsky D., Galton D. A. G. and Goldman J. M. (1986): Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant., 1, 53-60.
3. Argetsinger L. S., Campbell G. S., Yang X., Witthuhn B. A., Silvennoinen O., Ihle J. N. and Carter-Su C. (1993): Identification o JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell, 74, 237-244.
4. Bach J. F. and Chatenoud L. (2001): Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol., 19, 131-161.
5. Baeder W. L., Sredy J., Sehgal S. N., Chang J. Y. and Adams L. M. (1992): Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin. Exp. Immunol., 89, 174-178.
6. Behbod F., Erwin-Cohen R. A., Wang M. E., Trawick B. W., Qu X., Verani R., Kahan B. D., Stepkowski S. M. and Kirken R. A. (2001): Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat allografts. J. Immunol., 166, 3724-3732.
7. Bennett W. M., DeMattos A., Meyer M. M., Andoh T. and Barry J. M. (1996): Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int., 50, 1089-1100.
8. + hematopoietic progenitor cells. Cancer Invest., 14, 589-596.
9. Boker A., Rothenberg L., Hernandez C., Kenyon N. S., Ricordi C. and Alejandro R. (2001): Human islet transplantation: update. World J. Surg., 25, 481-486.
10. Bonnevie-Nielsen V. and Lernmark A. (1986): An H-2 allo-anti-serum preserves β-cell function in mice made diabetic by low-dose streptozotocin. Diabetes, 35, 570-573.
11. Bowman M. A., Leiter E. H. and Atkinson M. A. (1994): Prevention of diabetes in the NOD Mouse: implications for therapeutic intervention in human disease. Immunol. Today, 15, 115-120.
12. Bretzel R. G., Brendel M., Eckhard M., Brandhorst D., Jaeger C., Hatziagelaki E. and Federlin K. (2001): Islet transplantation: present clinical situation and future aspects. Exp. Clin. Endocrinol. Diabetes, 109, S384-S399.
13. Buckley R. H., Schiff R. I., Schiff S. E., Markert M. L., Williams L. W., Harville T. O. Roberts J. L. and Puck J. M. (1997): Human severe combined immunodeficiency: genetic phenotypic and functional diversity in one hundred eight infants. J. Pediatr., 130, 378-387.
14. Butturini A. and Gale R. P. (1994): Allogeneic bone marrow transplantation for leukemia. Curr. Opin. Hematol., 1, 402-405.
15. Calafiore R., Basta G., Falorni A., Ietropaolo M., Picchio M. L., Calcinaro F. and Brunetti P. (1993) Preventive effects of azathioprine (AZA) on the onset of diabetes mellitus in NOD mice. J. Endocrinol. Invest., 16, 869-873.
16. Cao X., Shores E. W., Hu-Li J., Anver M. R., Kelsall B. L., Rusell S.M., Drago J., Noguchi M., Grinberg A., Bloom E. T., Paul W. E., Katz S. I., Love P. E. and Leonard W. J. (1995): Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity, 2, 223-238.
17. Caravatti G., Meyer T., Fredenhagen A., Trinks U., Mett H. and Fabbro D. (1994): Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C. Bioorg. Med. Chem. Lett., 4, 399-404.
18. Cetkovic-Cvrlje M., Dragt A. L. and Uckun F. M. (2003): Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline] (JANEX-1). Drug Res., 53, 648-654.
19. Cetkovic-Cvrlje M., Dragt A. L., Vassilev L., Liu X. P. and Uckun F. M. (2003): Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin. Immunol., 106, 213-225.
20. Cetkovic-Cvrlje M., Roers B.A., Schonhoff D., Waurzyniak B., Liu X. P. and Uckun F. M. (2002): Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor. Leuk. Lymphoma, 43, 1447-1553.
21. Cetkovic-Cvrlje M., Roers B.A., Schonhoff D., Waurzyniak B., Liu X. P. and Uckun F. M. (2001): Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood, 98, 1607-1613.
22. Danzig M. and Cuss F. (1997) Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy, 52, 787-794.
23. Darnell J. E. J., Kerr I. M. and Stark G. R. (1994): Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264, 1415-1421.
24. Datta A. R., Barrett A. J., Jiang J. Z., Guimaraes A., Mavroudis D. A., van Rhee F., Gordon A. A. and Madrigal A. (1994): Distinct T-cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant., 14, 517-524.
25. De Vries J. E. (1994): Atopic allergy and other hypersensitivities. Curr. Opin. Immunol., 6, 835-837.
26. DiSanto J. P., Muller W., Guy Grand D., Fischer A. and Rajewsky K. (1995): Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor g chain. Proc. Natl. Acad. Sci. USA, 92, 377-381.
27. Drachenberg C. B., Klassen D. K., Weir M. R., Wiland A., Fink J. C., Bartlett S. T., Cangro C. B., Blahut S. and Papadimitriou J. C. (1999): Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation, 68, 396-402.
28. Elliott J. I., Dewchand H. and Altmann D. M. (1997): Streptozotocin-induced diabetes in mice lacking αβ T cells. Clin. Exp. Immunol., 109, 116-120.
29. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood, 86, 2821-2828.
30. Fiorucci G., Percario Z., Marcolin C., Coccia E., Affabris E. and Romeo G. (1995): Inhibition of protein phosphorylation modulates expression of the Jak family protein tyrosine kinases. J. Virol., 69, 5833-5837.
31. Formby B., Miller N., Garret R. and Peterson C. M. (1987): Effects of low-dose cyclosporine prophylaxis in NOD mice. J. Pharm. Exp. Ther., 241, 1106-1111.
32. Ghosh S., Zheng Y., Jun X., Narla R., Mahajan S., Navara C., Mao C., Sudbeck E. and Uckun F. M. (1998): α-Cyano-β-hydroxy-β-met hyl-N-[4-(trifluoromethoxy)phenyl]propenamide: an inhibitor of the EGF receptor tryosine kinase with potent cytotoxic activity against breast cancer cells. Clin. Cancer Res., 4, 2657-2668.
33. Gross D. J., Sidi H., Weiss L., Kalland T., Rosenmann E. and Slavin S. (1994): Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia, 37, 1195-1201.
34. + T-cells. J. Exp. Med., 184, 1-8.
35. Gurniak C.B. and Berg L.J. (1996): Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood, 87, 3151-3160.
36. Habib T., Senadheera S., Weinberg K. and Kaushansky K. (2002): The common g chain (γc) is required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry, 41, 8725-8731.
37. Hall B. M. (1991): Cells mediating allograft rejection. Transplantation, 51, 1141-1151.
38. Harpur A. G., Andreas A.C., Ziemiecki A., Aston R.R. and Wilks A. F. (1992): JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene, 7, 1347-1353.
39. Henslee-Downey P. J. (1995): Mismatched bone marrow transplantation. Curr. Opin. Oncol., 7, 115-121.
40. Herold K. C., Bluestone J. A., Montag A. G., Parihar A., Wiegner A.G., Gress R. E. and Hirsch R. (1992): Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes, 41, 385-391.
41. Herold K.C., Montag A. G. and Fitch F.W. (1987): Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin. Diabetes, 36, 796-801.
42. Herold K. C., Nagamatsu S., Buse J. B., Kulsakdinun P. and Steiner D.E. (1993): Inhibition of glucose-stimulated insulin release from βTC3 cells and rodent islets by an analog of FK506. Transplantation, 55, 186-192.
43. Ihle J. N. and Kerr I. R. (1995): JAKs and STATs in signaling by the cytokine receptor superfamily. Trends Genet., 11, 69-74.
44. Jindal R. M. (1994): Posttransplant diabetes mellitus - a review. Transplantation, 58, 1289-1298.
45. Jindal R. M. and Dubernard J.-M. (2000): Towards a specific immunosuppression for pancreas and islet grafts. Clin. Transplant., 14, 242-245.
46. Johnson B. D., McCabe C., Hanke C. A. and Truitt R. L. (1995): Use of anti-CD3 epsilon F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J. Immunol., 154, 5542-5554.
47. Johnson B. D. and Truitt R. L. (1992): A decrease in graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation, 54, 104-112.
48. Johnston J. A., Bacon C. M., Finbloom D. S., Rees R.C., Kaplan D., Shibuya K., Ortaldo J. R., Gupta S., Chen Y. Q., Giri J. D. and O'Shea J. J. (1995): Tyrosine phosphorylation and activation of STAT5, STAT3 and Janus kinases by interleukin 2 and 15. Proc. Natl. Acad. Sci. USA, 92, 5705-5709.
49. Kai N., Motojima K., Tsunoda T. and Kanematsu T. (1993): Prevention of insulitis and diabetes in NOD mice by administration of FK506. Transplantation, 55, 936-940.
50. Kane L. P., Lin J. and Weiss A. (2000): Signal transduction by the TCR for antigen. Curr. Opin. Immunol., 12, 242-249.
51. Kawamura M., McVicar D.W., Johnston J. A., Blake T. B., Chen Y. Q., Lal B. K., Lloyd A. R., Kelvin D. J., Staples J. E., Ortaldo J. R. and O'Shea J. J. (1994): Molecular cloning of L-JAK, a Janus family protein kinase expressed in natural killer cells and activated leukocytes. Proc. Natl. Acad. Sci. USA, 91, 6374-6378.
52. Kikutani, H. and Makino S. (1992): The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol., 51, 285-322.
53. Kino K., Mizumoto K., Sone T., Yamaji T., Watanabe J., Yamashita A., Yamaoka K., Shimizu K., Ko K. and Tsunoo H. (1990): An immunomodulating protein Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice. Diabetologia, 33, 713-718.
54. Kirken R. A., Erwin R. A., Taub D., Murphy W. J., Behbod F., Wang L., Pericle F. and Farrar W. L. (1999): Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T-cells. J. Leukoc. Biol., 65, 891-899.
55. Kolb H. and Kroncke K.-D. (1993): IDDM. Lessons from the low-dose streptozotocin model in mice. Diabetes Rev., 1, 116-126.
56. Korngold R., Leighton C. and Manser T. (1994): Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation, 56, 278-287.
57. Krolewski J. J., Lee R., Eddy R., Shows T. B. and Dalla-Favera R. (1990): Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene, 5, 277-282.
58. Kurasawa K., Koike T., Matsumura R., Takabayashi K., Tomioka H., Ito I. and Yoshida S. (1990): The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. Clin. Immunol. Immunopathol., 57, 274-279.
59. Lamers M., Antson A., Hubbard R., Scott R. and Williams D. (1999): Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol., 285, 713-725.
60. Leelasiri A., Greer J. P., Stein R. S., Goodman S., Brandt S. A., Edwards J. R. and Wolff S. N. (1995): Graft-versus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant., 15, 401-405.
61. Leiter E. H. and Atkinson M. (1997): NOD mice an related strains: research applications in diabetes, AIDS, cancer and other diseases. R.G. Landes Company, Austin, Texas, USA, 145-162.
62. Leonard W. J. (1996): The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med., 47, 229-239.
63. Leonard W. J. and O'Shea J. J. (1998): Jaks and Stats: Biological implications. Annu. Rev. Immunol., 16, 293-322.
64. Levy D.E. (1997): The house that Jak/Stat built. Cytokine Growth Factor Rev., 8, 81-90.
65. Li X. C., Ima A., Li Y., Zheng X. X., Malek T. R. and Strom T. B. (2000): Blocking the common γ-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J. Immunol., 164, 1193-1199.
66. Li X. C., Roy-Chaudbury P., Hancock W.W., Manfro R., Zand M. S., Li Y., Zheng X. X., Nickerson P. W., Steiger J., Malek T. R. and Strom T. B. (1998): IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection. J. Immunol., 161, 890-896.
67. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today, 16, 34-38.
68. Like A. A., Appel M. C., Williams R. M. and Rossini A. A. (1978): Streptozotocin-induced insulitis in mice. Lab. Invest., 38, 470-486.
69. Like A. A. and Rossini A. A. (1976): Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science, 193, 415-417.
70. Macchi P., Villa A., Giliani S., Sacco M. G., Frattini A., Porta F., Ugazio A. G., Johnston J. A., Cendotti F. and O'Shea J. J. (1995): Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature, 377, 65-68.
71. Mahajan S., Vassilev A., Sun N., Ozer Z., Mao C. and Uckun F. M. (2001): Transcription factor STAT5A i a substrate of Bruton's tyrosine kinase in B cells. J. Biol. Chem., 276, 31216-31228.
72. Mahon J.L., Dupre J. and Stiller C. R. (1993): Lessons learned from the use of cyclosporine for insulin-dependent diabetes mellitus. Ann. NY Acad. Sci., 696, 351-363.
73. Malaviya R., Chen C. L., Navara C., Malaviya R., Liu X. P., Keenan M., Waurzyniak B. and Uckun F. M. (2000): Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3″,5″-dibromo-4″-hydroxyphenyl) amino-6,7-dimethoxyquinazoline (WHI-P97). J. Pharmacol. Exp. Ther., 295, 912-926.
74. Malaviya R. and Uckun F. M. (1999): Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type 1 hypersensitivity reactions. Biochem. Biophys. Res. Commun., 257, 807-813.
75. Malaviya R. and Uckun F. M. (1999): Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J. Biol. Chem., 274, 27028-27038.
76. Manna S. and Aggarwal B. (1999): Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J. Immunol., 162, 2095-2102.
77. Marmont A.M., Horowitz M., Gale R., Sobocinski K., Ash R., van Bekkum D., Champlin R., Dicke K., Goldman J., Good R., Herzig R., Hong R., Masaoka T., Rimm A., Ringden O., Speck B., Weiner R. and Bortin M. (1991): T cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120-2130.
78. Martin P. J., Hansen J. A., Torok-Storb B., Durnam D., Przepiorka D., O'Quigley J., Sanders J., Sullivan K. M., Witherspoon R. P., Deeg H. J., Appelbaum F.R., Stewart P., Weiden P., Doney K., Buckner C. D., Clift R., Storb R. and Thomas E. D. (1988): Graft failure in patients receiving T-cell depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant., 3, 445-456.
79. Mattar T., Kochhar K., Bartlett R., Bremer E. and Finnegan A. (1993): Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett., 334, 161-164.
80. Meggio F., Donella D., Ruzzene M., Brunati A., Cesaro L., Guerra B., Meyer T., Mett H., Fabbro D., Furet P. et al. (1995): Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem., 234, 317-322.
81. Meydan N., Grunbereger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder S. J., Freedman M., Cohen A., Gazit A., Levitzki A. and Roifman C. M. (1996): Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 379, 645-648.
82. Min D. I. and Monaco A. P. (1991): Complications associated with immunosuppressive therapy and their management. Pharmacotherapy, 11, 119S-125S.
83. Miyagawa J., Yamamoto K., Hanafusa T., Itoh N., Nakagawa C., Otsuka A., Katsura H., Yamagata K., Miyazaki A., Kono N. et al. (1990): Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. Diabetologia, 33, 503-505.
84. Miyazaki T. and Taniguchi T. (1996): Coupling of the IL2 receptor complex with non-receptor protein tyrosine kinases. Cancer Surv., 27, 25-39.
85. Mori Y., Suko M., Okudaira H., Matsuba I., Tsuruoka A., Sasaki A., Yokoyama H., Tanase T., Shida T., Nishumira M., Terada E. and Ikeda Y. (1986): Preventive effects of cyclosporine on diabetes in NOD mice. Diabetologia, 29, 244-247.
86. Moriggl R., Sexl V., Piekorz R., Topham D. and Ihle, J. N. (1999): Stat5 activation is uniquely associated with cytokine signaling inperipheral T-cells. Immunity, 11, 225-230.
87. Moriggl R., Topham D.J., Teglund S., Sexl V., McKay C., Wang D., Hoffmeyer A., van Deursen J., Sangster Y., Bunting D. K., Grosveld G. C. and Ihle J. N. (1999): Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity, 10, 249-259.
88. Mortellaro A., Songia S., Gnochi P., Ferrari M., Fomasiero C., D'Alessio R., Isetta A., Colotta F. and Golay J. (1999): New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κB and AP-1 activation. J. Immunol., 162, 7102-7109.
89. Mueller R., Davis J. D., Krahl T. and Sarvetnick N. (1997): IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J. Immunol., 159, 1599-1603.
90. Muller M., Briscoe J., Laxton C., Guschin D., Ziemicki A., Silvennoinen O., Harpur A. G., Barbieri G., Witthuhn B. A. and Schindler C. (1993): The protein tyrosine kinase JAK1 complements defects in interferon-α/β and γ signal transduction. Nature, 366, 114-116.
91. Nakano H., Kobayashi E., Takahashi I., Tamaoki T., Kuzuu Y. and Iba H. (1987): Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J. Antibiot., 40, 706-708.
92. Nicoletti F., Zaccone P., Dimarco R., Magro G., Grasso S., Morrone S., Santoni A., Tempera G., Meroni P. L. and Bendtzen K. (1995): Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology, 85, 645-650.
93. Noguchi M., Yi H., Rosenblatt H. M., Filipovich A. H., Adelstein S., Modi W. S., McBride O. W. and Leonard W. J. (1993): Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell, 73, 147-157.
94. Nosaka T., van Deursen J. M., Tiipp R. A., Thierfelder W. E., Witthuhn B. A., McMickle A. P., Doherty P. C., Grosveld G. C. and Ihle J. N. (1995): Defective lymphoid development in mice lacking Jak3. Science, 270, 800-802.
95. O'Reilly R. J. (1983): Allogeneic bone marrow transplantation: current status and future directions. Blood, 62, 941-964.
96. O'Reilly R.J. and Papadopoulos E. B. (1997): Allogeneic transplantation. In Hokland J. F. et al. (eds.): Cancer medicine. 4th Edition. William and Wilkins, Baltimore, vol. 1, 1295-1324.
97. Park S. Y., Saijo K., Takahashi T., Osawa M., Arase H., Hirayama N., Miyake K., Nakauchi H., Shirasawa T. and Saito T. (1995): Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity, 3, 771-782.
98. Pennline K. J., Roquegaffney E. and Monahan M. (1994): Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol., 71, 169-175.
99. Philips J. M., Parish N. M., Drage M. and Cooke A. (2001): Cutting edge: interactions through the IL-10 receptor regulate autoimmune diabetes. J. Immunol., 167, 6087-6091.
100. Poynton C. (1988): T cell depletion in bone marrow transplantation. Bone Marrow Transplant., 3, 265-279.
101. Rabinovitch A. (1998): An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev., 14, 129-151.
102. Rakieten N. (1963): Studies on the diabetogenic action of streptozotocin. Cancer Chemother. Rep., 29, 91-98.
103. Ramsay N. K. and Kersey J. H. (1990): Indications for marrow transplantation in acute lymphoblastic leukemia. Blood, 75, 815-818.
104. Rossini A. A., Appel M. C., Williams R. M. and Like A. A. (1977): Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes, 29, 916-920.
105. Russell S.M., Johnston J. A., Noguchi M., Kawamura M., Bacon C. M., Friedmann M., Berg M., McVicar D. W., Witthuhn B. A. and Silvennoinen O. (1994): Interaction of IL-2R β and γc chains with Jakl an Jak3: implications for XSCID and XCID. Science, 266, 1042-1045.
106. Russell S.M., Tayebi N., Nakajima H., Riedy M. C., Roberts J. L., Aman M. J., Migone T.S., Noguchi M., Markert M. L. and Buckley R. H. (1995): Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science, 270, 797-800.
107. Saemann M. D., Bohmig G. A., Osterreicher C. H., Staffler G., Diakos C., Krieger P. M., Horl W. H., Stockinger H. and Zlabinger G. J. (2000): Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490. Transplantation, 70, 1215-1225.
108. Saemann M. D., Zeyda M., Diakos C., Szekeres A., Bohmig G.A., Kelemen P., Parolini O., Stockinger H., Prieschl E. E., Stulnig T. M., Baumruker T. and Zlabinger G. J. (2003): Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation, 75, 1864-1872.
109. Salam A. and Waer M. (1996): Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. Transplantation, 61, 826-830.
110. Schorle H.T., Holyschke T., Hunig T., Schimpl A. and Horak I. (1991): Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature, 252, 621-624.
111. Shapiro A. M., Lakey J. R. T., Ryan E. A., Korbutt G. S., Toth E., Warnock G. L., Kneteman N. M. and Rajotte R. V. (2000): Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med., 343, 230-238.
112. Shapiro A. M., Ryan E. A. and Lakey J. R. T. (2001): Pancreatic islet transplantation in the treatment of diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab., 15, 241-264.
113. Sharfe N., Dadi H. K., O'Shea J. J. and Roifman C. M. (1997): Jak3 activation in human lymphocyte precursor cells. Clin. Exp. Immunol., 108, 552-556.
114. Siemasko K., Chong A., Jack H., Gong H., Williams J. and Finnegan A. (1998): Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol., 160, 1581-1588.
115. Steiger J., Nickerson P. W., Steurer M., Moscovitch-Lopatin M. and Strom T. B. (1995) IL-2 knockout recipient mice reject islet cell allografts. J. Immunol., 155, 489-498.
116. Stepkowski S. M., Erwin-Cohen R. A., Behbod F., Wang M. E., Qu X., Tejpal N., Nagy Z. S., Kahan B. D. and Kirken R. A. (2002): Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood, 15, 680-689.
117. Strandell E. and Sandler S. (1992): Protection against hyperglycemia in female nonobese diabetic mice treated with 15-deoxyspergualin. Autoimmunity, 14, 159-165.
118. Sudbeck E. A., Liu X.-P., Narla R. K., Mahajan S., Ghosh S., Mao C. and Uckun F. M. (1999): Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin. Cancer Res., 5, 1569-1582.
119. Sugamura K., Asao H., Kondo M., Tanaka N., Ishii N., Ohbo K., Nakamura M. and Takeshita T. (1996): The interleukin-2 receptor γ-chain: its role in multiple cytokine receptor complexes and T cell development in XSCID. Annu. Rev. Immunol., 14, 179-205.
120. Sutherland D. E., Gruessner R. W. G. and Gruessner A. C. (2001): Pancreas transplantation for treatment of diabetes mellitus. World J. Surg., 25, 487-496.
121. Suzuki H. T., Kundig M., Furlonger C., Wakeham A., Timms E., Matsuyama T., Schmits R., Simard J. J., Ohashi P. S. and Griesser H. (1995): Deregulated T cell activation an autoimmunity in mice lacking interleukin-2 receptor β. Science, 268, 1472-1476.
122. - and CD8-mediated graft-versus-leukemia effects. Blood, 83, 2560-2569.
123. Takahashi T. and Shirasawa T. (1994): Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett., 342, 124-128.
124. Theze J., Alzari P. M. and Bertoglio J. (1996): Interleukin-2 and its receptors: recent advances and new immunological functions. Immunol. Today, 17, 481-486.
125. Thomas H. E. and Kay T. W. H. (2000): Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes Metab. Res. Rev., 16, 251-261.
126. + T-cells. J. Immunol., 163, 5411-5417.
127. Thomis D. C., Gurniak C. B., Tivol E., Sharpe A. H. and Berg L. J. (1995): Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science, 270, 794-797.
128. Thompson J. E., Cubbon R. M., Cummings R. T., Wicker L. S., Frankshun R., Cunningham B. R., Camron P. M., Meinke P. T., Liverton N., Weng Y. and DeMartino J. A. (2002): Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett., 12, 1219-1223.
129. Tian J., Olcott A. P., Hanssen L. R., Zekzer D., Middleton B. and Kaufman D. L. (1998): Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Immunol. Rev., 164, 119-127.
130. Tomita K., Saijo K., Yamasaki S., Lida T., Nakatsu F., Arase H., Ohno H., Shirasawa T., Kuriyama T., O'Shea J. J. and Saito T. (2001): Cytokine-independent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex. J. Biol. Chem., 276, 25378-25385.
131. Tortolani P. J., Lal B. K., Riva A., Johnston J. A., Chen Y. Q., Reaman G. H., Beckwith M., Longo D., Ortaldo J. R. and Bhatia K. (1995): Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J. Immunol., 155, 5220-5226.
132. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant., 8, 51-58.
133. Tsukada N., Kobata T., Aizawa Y., Yagita H. and Okumura K. (1999): Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood, 93, 2738-2747.
134. Uckun F. M., Ek O., Liu X.-P. and Chen C.-L. (1999): In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]. Clin. Cancer Res., 5, 2954-2962.
135. Uckun F. M., Roers B. A., Waurzyniak B. and Cetkovic-Cvrlje M. (2002): Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood, 99, 4192-4199.
136. Van Lochem E., De Gast B. and Goulmy E. (1992): In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant., 10, 181-183.
137. Velazquez L., Fellous M., Stark G. R. and Pellegrini S. (1992): A protein tyrosine kinase in the interferon o¿13(x/p signaling pathway. Cell, 70, 313-322.
138. Vourka-Karussis U., Karrusis D., Ackerstein A. and Slavin S. (1995): Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/mice. Exp. Hematol., 23, 196-201.
139. Wang L., Kirken R., Erwin R., Yu C. and Farrar W. (1999): JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tryphostin AG-490 regulation of IL-2-mediated T cell response. J. Immunol., 162, 3897-3904.
140. Wasik M., Nowak I., Zhang Q. and Shaw L. (1998): Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine. Leuk. Lymphoma, 28, 551-560.
141. Weiss A. and Littman D. R. (1994): Signal transduction by lymphocyte antigen receptors. Cell, 76, 263-274.
142. Wijdicks E. F. (2001): Neurotoxicity of immunosuppressive drugs. Liver Transpl., 7, 937-942.
143. Wilks A. F., Harpur A. G., Kurban R. R., Ralph S. J., Zurcher G. and Ziemiecki A. (1991): Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol., 11, 2057-2065.
144. Willerford D. M., Chen J., Ferry J. A., Davidson L., Ma A. and Alt F.W. (1995): Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid compartment. Immunity, 3, 521-530.
145. Witthuhn B. A., Quelle F. W., Silvennoinen O., Yi T., Tang B., Miura O. and Ihle J. N. (1993): JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 74, 227-236.
146. Wong S. F. and Janeway C. A. (1999): The role of CD4 vs. CD8 T cells in IDDM. J. Autoimmun., 13, 290-295.
147. Yamashita N., Kazuo S., Kitamura M., Wakao H., Furihata K., Furihata K., Hayakawa Y., Miyajima A. and Seto H. (1997): Cyovaricin B, a new inhibitor of JAK-STAT signal transduction produced by stroptomyces torulosus. J. Antibiot., 50, 440-442.
148. Yang Z., Chen M., Wu R., Fialkow L. B., Bromberg J. S., McDuffie M., Naji A. and Nadler J. L. (2002): Suppression of autoimmune diabetes by viral IL-10 gene transfer. J. Immunol., 168, 6479-6485.
149. Yoshida K. and Kikutani H. (2000): Genetic and immunological basis of autoimmune diabetes in the NOD mouse. Rev. Immunogenet., 2, 140-146.
150. Yun S., Sawyer G. J., Zhang X., Gustafsson K. and Fabre J. W. (2000): The role of IL-2 in allograft rejection - a lesson learned from experimental work. Transplantation, 69, 2480-2483.
151. Zeng Y., Ricordi C., Lendoire J., Carroll P. B., Alejandro R., Bereiter D. R., Tzakis A. and Starzl T. E. (1993): The effect of prednisone on pancreatic islet autografts in dogs. Surgery, 113, 98-102.
152. Zheng X. X., Steele A.W., Hancock W. W., Steven A. C., Nickerson P. W., Roy-Chaudhury P., Tian Y. and Strom T. B. (1997): A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J. Immunol., 158, 4507-4513.